Holen Sie sich die Stockscreener-App
11.02
0.99%
-0.11
Handel nachbörslich:
11.02
Schlusskurs vom Vortag:
$11.13
Offen:
$11.2
24-Stunden-Volumen:
379.52K
Relative Volume:
0.56
Marktkapitalisierung:
$665.48M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.99M
KGV:
-5.1503
EPS:
-2.1397
Netto-Cashflow:
$-79.92M
1W Leistung:
-6.05%
1M Leistung:
-8.17%
6M Leistung:
-60.20%
1J Leistung:
-37.78%
1-Tages-Spanne:
$10.88
$11.59
1-Wochen-Bereich:
$10.88
$11.98
52-Wochen-Spanne:
$10.52
$34.48
Oculis Holding Ag Stock (OCS) Company Profile
Firmenname
Oculis Holding Ag
Sektor
Branche
Telefon
-
Adresse
-
Compare OCS vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
11.02 | 672.12M | 0 | -117.99M | -79.92M | -2.1397 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-19 | Eingeleitet | JP Morgan | Overweight |
| 2025-08-27 | Eingeleitet | Needham | Buy |
| 2023-12-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-10-05 | Eingeleitet | Stifel | Buy |
| 2023-06-14 | Eingeleitet | BofA Securities | Buy |
| 2023-06-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-06-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-10 | Eingeleitet | Pareto | Buy |
| 2023-04-28 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Oculis Holding Ag Aktie (OCS) Neueste Nachrichten
Oculis Holding AG (OCS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oculis Holding AG (OCS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oculis Holding AG (OCS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oculis Holding AG (OCS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oculis Holding AG (OCS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oculis Holding AG (OCS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
OCS|Oculis Holding AG|Price:11.130|Chg%:-0.310 - TradingKey
Oculis Holding AG Revenue Breakdown – NASDAQ:OCS - TradingView
OCS|Oculis Holding AG|Price:11.040|Chg%:-0.090 - TradingKey
Oculis Holding AG (OCS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Technical Reactions to OCS Trends in Macro Strategies - Stock Traders Daily
Guggenheim initiates coverage of Oculis Holding (OCS) with buy recommendation - MSN
Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Gross - The National Law Review
Number of shareholders of Oculis Holding AG – NASDAQ:OCSAW - TradingView
Price to sales forward of Oculis Holding AG – NASDAQ:OCSAW - TradingView
Price to book forward of Oculis Holding AG – NASDAQ:OCSAW - TradingView
Oculis Holding AG (OCS) Slightly Gains, Nearing Key Resistance LevelVolume Nodes - dars.gov.et
Bronstein, Gewirtz & Grossman, LLC Is Investigating Oculis Holding AG (OCS) And Encourages Investors to Connect - The National Law Review
Enterprise value to revenue forward of Oculis Holding AG – NASDAQ:OCSAW - TradingView
Enterprise value to EBITDA forward of Oculis Holding AG – NASDAQ:OCSAW - TradingView
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - marketscreener.com
Oculis director's RSUs vest and settle, signali... - Pluang
Price to book forward of Oculis Holding AG – SWB:CR5 - TradingView
Price to earnings forward of Oculis Holding AG – NASDAQ:OCS - TradingView
Price to sales forward of Oculis Holding AG – NASDAQ:OCS - TradingView
Enterprise value to revenue forward of Oculis Holding AG – SWB:CR5 - TradingView
Oculis Holding AG Warrants 2023-06.03.28 on OCULIS HOLDING Financial Disclosures & SEC Filings - TradingView
Oculis stock gains after FDA trial design agreement - Investing.com
Oculis stock gains after FDA trial design agreement By Investing.com - Investing.com Nigeria
Oculis to present updates on late-stage eye dis... - Pluang
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference - The Manila Times
Oculis to Participate in Piper Sandler Virtual Ophthalmology Conference Fireside Chat - Quiver Quantitative
Trading the Move, Not the Narrative: (OCS) Edition - Stock Traders Daily
Oculis Updates Investor Presentation, Emphasizing Late-Stage Neuro-Ophthalmic Pipeline and Cash Runway - TipRanks
Oculis Holding AG Actuals & Estimates (NASDAQ:OCS) - TradingView
Oculis Holding AG Warrants (OCSAW) See Upward Momentum Amid Modest GainsSign of Strength - dars.gov.et
Oculis (NASDAQ: OCS) details late-stage eye drugs and cash runway into 2029 - Stock Titan
OCS Forecast — Price Target — Prediction for 2027 - TradingView
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AGOCS - PR Newswire
Oculis Holding AG (OCS) Slips 1.37% as Shares Test Key Support LevelDip Buy Trade - dars.gov.et
OCSOculis Holding AG Revenue Breakdown - Finviz
Pomerantz investigates Oculis over failed drug trials and stock drop - Pluang
Oculis Holding AG (OCS) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Focuses on Pipeline ProgressCash Flow Report - dars.gov.et
Oculis Holding AG (OCS) Edges Lower Amidst Sector Headwinds; Support Levels in FocusRegression Channel - dars.gov.et
(OCS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Oculis Holding AG (OCS) Institutional Confidence - TradingKey
OCS News | OCULIS HOLDING AG (NASDAQ:OCS) - ChartMill
Oculis Holding AG (OCS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oculis Holding AG (OCSAW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oculis Holding AG (OCSAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Finanzdaten der Oculis Holding Ag-Aktie (OCS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):